CRT-106 Endothelial Dysfunction is Not Associated With No-reflow During Primary PCI  by Sultan, Ayyaz et al.
S10 J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 8 , N O . 2 , S U P P L S , 2 0 1 5
C
O
R
O
N
A
R
Ypatients, age ranging from 25 to 101 years. Ninety two patients presented in CS. We
did not perform Allen’s test in any patients, presence of pulse was enough to proceed.
We assessed in-hospital complications.
RESULTS Out of all patients, 94.6% patients underwent PPCI through TR-TU vascular
access (96.9% in those without CS and 77.8% of those with CS). We failed to proceed
TR only in 2 patients. Three patients had occluded radial artery after previous pro-
cedure, in whom we performed PCI through TU approach in same arm. Total of 8
patients had procedure performed through TU access .
For all patients, mean door to balloon time was 49.8 minutes (door to cathlab: 23.8
mins and cath-lab to balloon time: 25.9 mins); call to balloon time was 115.1 mins,
without any signiﬁcant difference between those with / without CS. Contrast volume,
radiation dose and ﬂuoroscopy time were no different between groups.
In-hospital mortality was 1.5% in those without cardiogenic shock and 23.9% in
those with cardiogenic shock. None of the patients who had PPCI through TR-TU
access had any vascular complication. Only 6 patients who had PPCI through TF had
localized bleeding, without need for blood transfusion.
CONCLUSIONS 1. Performing PPCI through TR-TU access is safe, even in those with
CS, previous CABG and occluded radial artery after previous PCI.
2. Allen’s test is not a prerequisite, and should not be a limiting factor.
3. Once operators are well trained, majority of patients can have intervention
performed through TR-TU access without any time delay in completion of successful
intervention.
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INTRODUCTION Coronary no-reﬂow during primary PCI is a predictor of poorer car-
diovascular outcome. Both endothelial dysfunction and no-reﬂow involves abnormal
vascular function and hemostasis. Therefore, our aim was to assess the association
between risk factors, endothelial dysfunction and no reﬂow during primary PCI.
METHODS Thirty consecutive patients with STEMI and normal ﬂow during primary
PCI were compared to 19 consecutive patients who had no reﬂow. All subjects un-
derwent assessment of endothelial function (reactive hyperemia index- RHI) within
48-72 h post PCI using the EndoPAT device.
RESULTS Age, sex, and frequency of hypertension were similar in both groups.
Smokers were less likely to have no-reﬂow (Table). Post PCI there was less ST-
segment resolution in the no-reﬂow group (48%þ7 vs 81%þ6; p¼0.001). Patients who
had no reﬂow had subsequently lower ejection fraction (39þ10 vs 47þ10; p¼0.015).
There was no difference in vascular function (RHI) between groups. (Figure)
CONCLUSION Systemic vascular function is not associated with coronary no reﬂow.CRT-107
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BACKGROUND Glycoprotein IIb/IIIa inhibition has been a mainstay in acute
myocardial infarction intervention. Major bleeding is a predictor of adverse outcomes
in ST elevation myocardial infarction (STEMI).
OBJECTIVES To determine the safety and bleeding outcomes of abbreviated
compared to standard infusions of the glycoprotein IIb/IIIa inhibitor eptiﬁbatide in
the setting of primary PCI for STEMI.
METHODS We analyzed a retrospective cohort of 93 STEMI patients who received
abbreviated (<18 hours) infusion of eptiﬁbatide and compared them to 91 STEMI
patients with standard (18 hours) infusion in primary PCI, from June 2009 to June
2011, at a single cardiac centre. Detailed chart review of demographic and clinical
characteristics, times to intervention, complications, electrocardiographic (ECG)
ﬁndings, bleeding, ejection fraction (EF), and stent thrombosis data was performed.
Descriptive statistics were utilized to outline safety and efﬁcacy outcomes. A
p-value <0.05 was considered signiﬁcant.
RESULTS Therewas no signiﬁcant difference between the two groups in complications
including GI bleeding, hematoma larger than 5 cm, ﬁstula or pseudo-aneurysm, retro-
peritoneal hemorrhage (RPH) or hemoglobin drop more than 50 g/L. Closure devices
were deployedmore in abbreviated infusion (65%vs. 44%, p-value: 0.004). Therewas a
trend towards improved ST elevation resolution > 50% in standard infusion (78% vs.
66%, p-value: 0.06) and CK peaked higher in abbreviated infusion (2088.9 þ/- 1982 vs.
1565þ/- 1545, p-value; 0.05). There was no signiﬁcant difference in stent thrombosis or
EF (47.25% þ/- 9.46 vs. 49.4% þ/- 9.2 for abbreviated and standard infusion respec-
tively, p-value: 0.12). There was no signiﬁcant difference in transfusion (3% vs. 5% for
abbreviated and standard infusion respectively, p-value: 0.44) or death (3.2% vs. 1.1%
for abbreviated and standard infusion respectively, p-value: 0.37).
CONCLUSIONS Abbreviated duration glycoprotein IIb/IIIa inhibition may be a safe
and novel alternative to standard infusion during STEMI. Although there was no
signiﬁcant difference in bleeding or vascular complications between abbreviated and
standard infusion groups, along with a trend towards better ST resolution and lower
CK in standard infusion group, but there was no signiﬁcant difference in stent
thrombosis, EF or death between the two groups. Further large prospective ran-
domized controlled trials are indicated to study this approach to reduce bleeding in
this high risk population.
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BACKGROUND Little information was available regarding the clinical outcomes of
drug-eluting stents (DES) in octogenarians with acute myocardial infarction (AMI).
